About Outset Medical, Inc.
https://www.outsetmedical.comOutset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.
CEO
Leslie L. Trigg
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-03-20 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 3 of 61
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
FMR LLC
Shares:2.66M
Value:$14.02M
PFM HEALTH SCIENCES, LP
Shares:1.73M
Value:$9.1M
ALYESKA INVESTMENT GROUP, L.P.
Shares:1.61M
Value:$8.49M
Summary
Showing Top 3 of 115
About Outset Medical, Inc.
https://www.outsetmedical.comOutset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $29.43M ▼ | $27.06M ▼ | $-17.84M ▲ | -60.61% ▼ | $-1 ▲ | $-13.64M ▲ |
| Q2-2025 | $31.42M ▲ | $28.73M ▲ | $-18.54M ▲ | -59.01% ▲ | $-1.04 ▲ | $-16.86M ▲ |
| Q1-2025 | $29.75M ▲ | $27.46M ▼ | $-25.78M ▼ | -86.66% ▲ | $-7.44 ▼ | $-20.81M ▼ |
| Q4-2024 | $29.47M ▲ | $32.61M ▼ | $-25.64M ▲ | -87.01% ▲ | $-0.5 ▲ | $-18.41M ▲ |
| Q3-2024 | $28.67M | $33.66M | $-27.94M | -97.47% | $-0.55 | $-19.54M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $178.64M ▼ | $277.25M ▼ | $134.89M ▲ | $142.37M ▼ |
| Q2-2025 | $184.09M ▼ | $288.8M ▼ | $134.02M ▲ | $154.78M ▼ |
| Q1-2025 | $189M ▲ | $301.21M ▲ | $131.34M ▼ | $169.87M ▲ |
| Q4-2024 | $158.69M ▼ | $275.8M ▼ | $248.98M ▲ | $26.82M ▼ |
| Q3-2024 | $175.63M | $292.89M | $245.07M | $47.82M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-17.84M ▲ | $-6.32M ▼ | $2.97M ▲ | $231K ▲ | $-3.12M ▲ | $-6.48M ▼ |
| Q2-2025 | $-18.54M ▲ | $-4.82M ▲ | $-31.16M ▲ | $-384K ▼ | $-36.37M ▲ | $-5.12M ▲ |
| Q1-2025 | $-25.78M ▼ | $-25.66M ▼ | $-78.08M ▼ | $55.66M ▲ | $-48.09M ▼ | $-25.79M ▼ |
| Q4-2024 | $-25.64M ▲ | $-16.49M ▲ | $108.15M ▲ | $-938K ▼ | $90.73M ▲ | $-16.53M ▲ |
| Q3-2024 | $-27.94M | $-20.57M | $15.88M | $121K | $-1.24M | $-20.96M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Consoles Product | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Consumables Product | $30.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Product | $40.00M ▲ | $20.00M ▼ | $20.00M ▲ | $20.00M ▲ |
 Service And Other Revenue | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
CEO
Leslie L. Trigg
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-03-20 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 3 of 61
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
FMR LLC
Shares:2.66M
Value:$14.02M
PFM HEALTH SCIENCES, LP
Shares:1.73M
Value:$9.1M
ALYESKA INVESTMENT GROUP, L.P.
Shares:1.61M
Value:$8.49M
Summary
Showing Top 3 of 115